Daan van Well, Chief Legal Officer of SOPHiA GENETICS SA, filed a Form 4 on November 17, 2026, disclosing the sale of 1,224 ordinary shares on November 16, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Daan van Well, Chief Legal Officer of SOPHiA GENETICS SA
  • Transaction: Disposition (code S) of 1,224 ordinary shares on November 16, 2026
  • Weighted average price: $7.7301 per share, with individual transactions ranging from $7.43 to $8.10
  • Post-transaction ownership: 330,081 ordinary shares held directly following the reported sale
  • 10b5-1 plan: The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c)
  • Filing signed: By Elimara Brunetto as Attorney-in-Fact for Daan van Well, dated November 17, 2026

Van Well's November 2026 Share Sale Under Rule 10b5-1 Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Daan van Well, the Chief Legal Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), disposed of 1,224 ordinary shares on November 16, 2026. The filing states that the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), which provides an affirmative defense for pre-planned securities transactions by corporate insiders.

The filing reports a weighted average sale price of $7.7301 per share. As noted in the filing's explanation of responses, the shares were sold in multiple transactions at prices ranging from $7.43 to $8.10, inclusive. The filing further states that van Well "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Following the reported transaction, the filing discloses that van Well directly holds 330,081 ordinary shares. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Elimara Brunetto as Attorney-in-Fact for Daan van Well and filed on November 17, 2026.

What Was Disclosed

SOPHiA GENETICS SA's Chief Legal Officer, Daan van Well, disclosed a sale of 1,224 ordinary shares on November 16, 2026, at a weighted average price of $7.7301, executed under a pre-established Rule 10b5-1 trading plan, leaving him with 330,081 directly held shares.